10-K: Nephros Reports Strong 2025 Growth, Net Income Soars 1,514%

Nephros, Inc. announced a significant increase in net income and revenue for fiscal year 2025, driven by higher programmatic sales and emergency response business, despite ongoing tariff impacts and an identified material weakness in internal controls.

Summary

• Net revenues increased 33% to $18.789 million in 2025 from $14.162 million in 2024.
• Net income surged by 1,514% to $1.194 million in 2025, up from $0.074 million in 2024.
• Gross profit margin remained stable at 62% for both 2025 and 2024, though tariffs impacted margins in the second half of 2025.
• Operating income dramatically increased to $1.146 million in 2025 from $0.006 million in 2024.
• Cash and cash equivalents rose to $5.4 million at year-end 2025 from $3.76 million at year-end 2024.
• The company generated $1.645 million in net cash from operating activities in 2025, a significant improvement from using $0.492 million in 2024.
• A material weakness in internal control over financial reporting was identified related to revenue recognition for combined product and service contracts.
• The exclusive License and Supply Agreement with Medica S.p.A. was extended until December 31, 2030, with minimum annual purchase commitments ranging from $4.976 million in 2026 to $6.3 million in 2030.
• The company introduced a new commercial water filter solution validated for the reduction of Total PFAS compounds.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report due to significant financial improvements, including strong revenue and net income growth, and positive operating cash flow. However, the identified material weakness in internal controls and ongoing tariff impacts introduce notable uncertainties.

Positives

• Net income increased by 1,514% to $1.194 million in 2025.
• Total net revenues grew by 33% to $18.789 million in 2025.
• Operating income saw a substantial increase to $1.146 million in 2025 from $0.006 million in 2024.
• Net cash provided by operating activities improved significantly to $1.645 million in 2025, compared to net cash used of $0.492 million in 2024.
• Cash and cash equivalents increased to $5.4 million as of December 31, 2025, from $3.76 million in 2024.
• Working capital improved to $8.456 million in 2025 from $6.736 million in 2024.
• Successful extension of the exclusive License and Supply Agreement with Medica S.p.A. until December 31, 2030.
• Introduction of a new commercial water filter solution validated for Total PFAS reduction, expanding the product portfolio.
• Strong reorder activity and the addition of several new active sites contributed to higher programmatic revenue.
• Solid growth in the emergency response business and significant growth in service revenue.

Negatives

• An accumulated deficit of $143.1 million as of December 31, 2025, despite recent profitability.
• Identified a material weakness in internal control over financial reporting related to revenue recognition for service-based sales contracts.
• Gross profit margins eroded in the second half of 2025 due to the impact of tariffs, which are anticipated to continue affecting margins.
• Research and development expenses increased by 48% to $1.339 million in 2025.
• Selling, general and administrative expenses increased by 17% to $9.0 million in 2025.
• Other expense, net, increased significantly to $78,000 in 2025, primarily due to foreign currency transaction losses.
• Reliance on a single-source supplier (Medica S.p.A.) for proprietary filter material, creating vulnerability to supply problems and price fluctuations.
• Minimum annual purchase obligations under the Medica agreement, with failure to meet them potentially leading to termination of exclusivity.
• Revenue from the emergency response business is unpredictable, leading to potential quarter-to-quarter fluctuations.
• The company operates with a limited two-person senior management team, posing risks in attention to operations and succession planning.
• The U.S. Supreme Court ruled IEEPA-based tariffs invalid, but new temporary global tariffs were announced, creating ongoing uncertainty and potential cost increases.
• The company has never paid dividends and does not intend to in the foreseeable future.

Risks

• Significant challenges in obtaining market acceptance of products could adversely affect potential sales and revenues.
• Product-related deaths, serious injuries, or malfunctions could trigger recalls, lawsuits, and expenses, limiting revenue generation.
• Potential liability associated with product production, marketing, and sale, with defense expenses depleting assets and generating negative publicity.
• Violation of FDC Act or other statutes/regulations could lead to enforcement actions by the FDA or other governmental agencies.
• Inability to obtain funding when needed or on favorable terms to continue operations.
• Insufficient capital to successfully implement the business plan.
• Inability to effectively market and sell products in new or existing markets.
• Inability to sell water filtration products at competitive or profitable prices.
• Increased costs and/or disruptions in the supply chain due to U.S. tariffs.
• Encountering unanticipated internal control deficiencies or weaknesses or ineffective disclosure controls and procedures.
• Inability to obtain appropriate or necessary regulatory approvals to achieve the business plan.
• Inability to secure or enforce adequate legal protection, including patent protection, for products.
• Inability to achieve sales growth in key geographic markets.
• Limited history of profitability and a significant accumulated deficit, with no guarantee of maintaining or improving profitability.
• Inability to sustain significant revenue growth for an extended period could adversely affect financial results and stock price.
• Failure to successfully scale-up production of products could limit profitability.
• Reliance on a limited number of independent manufacturers, making the company vulnerable to supply problems and price fluctuations.
• Unpredictable revenue from the emergency response business, leading to significant period-to-period fluctuations.
• Inability to develop adequate distribution, customer service, and technical support networks could impair marketing and sales.
• Significant developments from recent and potential changes in United States tariff policies could materially adversely affect the company.
• Failure to meet minimum purchase obligations under the License and Supply Agreement with Medica could result in termination of exclusivity and impact product supply.
• Operating with a limited senior management team and high dependence on sales and marketing personnel, risking harm if unable to attract and retain talent.
• Reliance on information technology systems and network infrastructure, with risks of breaches, cyber attacks, or disruptions adversely affecting business.
• Product liability associated with products, particularly for healthcare, could deplete assets and harm reputation.
• Risk of product-related deaths, serious injuries, or malfunctions, triggering recalls, lawsuits, and regulatory actions.
• Failure of employees or third-party contractors to perform installation and service adequately could harm business and reputation.
• New water filter products may require regulatory approvals, and delays or failures could limit market entry and revenue.
• Significant additional governmental regulation could subject the company to unanticipated delays.
• Inability to maintain sufficient quality controls could lead to withdrawal, delay, or denial of product approvals.
• Protecting intellectual property in technology through patents may be costly and ineffective, and patents may not be broad enough to prevent competitors or could be invalidated.
• Litigation and other proceedings relating to patent matters can be expensive and time-consuming.
• Inability to secure and enforce protection of trade secrets could allow competitors access to proprietary information.
• The prices at which shares of the common stock trade have been and will likely continue to be volatile.
• Common stock could be further diluted as a result of the issuance of additional shares of common stock, warrants or options.
• Market sales of large amounts of common stock, or the potential for those sales, may depress the market price.
• Several provisions of the Delaware General Corporation Law, the company's certificate of incorporation, and bylaws could discourage, delay, or prevent a merger or acquisition.
• As a smaller reporting company with little or no name recognition and several risks, the company is not likely to generate widespread interest in its common stock, leading to high volatility and potential decline in value.
• Securities class action litigation is often brought against public companies following periods of volatility in the market price of their securities.
• Directors, executive officers, and Wexford Capital control a significant portion of the company's stock and could have sufficient voting power to control corporate matters.
• Future sales of common stock by stockholders could depress the market price of common stock.

Future Outlook

The company believes its cash balances will be sufficient to fund current operating plans for at least the next 12 months. Operating plans are designed to control costs and increase revenue to generate sufficient cash flows. Tariffs are anticipated to continue affecting gross profit margins unless U.S. tariff policy changes. The company intends to continue developing new products and market them globally.

Management Comments

• "We believe that continued enforcement of these requirements and the growing emphasis on effective water management programs may have a positive impact on demand for our HAI-inhibiting microand ultrafilters."
• "Over time, we believe that the same water safety management programs currently underway at medical facilities may migrate to commercial markets."
• "We believe that we have an opportunity to offer unique expertise and products to the commercial market."
• "We believe that our relations with our employees are good."
• "We intend to focus on maintaining our current good relations with our employees and continuing to develop and explore ways to collaborate with our employees and create a well-regarded workplace."

Industry Context

StockSavvy.ai notes that Nephros's strong performance in medical-grade water filtration aligns with increasing regulatory scrutiny and awareness of waterborne pathogens in healthcare settings, driven by CMS and CDC guidelines. The expansion into commercial markets with PFAS reduction capabilities positions the company to capitalize on growing public and regulatory concerns over "forever chemicals" in drinking water, potentially mirroring the demand for water safety management seen in medical facilities. The shift from an exclusive distributor in foodservice/hospitality to broadening market reach suggests an adaptation to competitive dynamics and a strategy to capture a larger share of the diverse commercial filtration market.

Comparison to Industry Standards

• Nephros's FDA 510(k)-cleared Class II medical devices for infection control and dialysis water filtration offer validated safety and performance, a key differentiator in highly regulated healthcare environments compared to general-purpose filters.
• The company's ultrafilters, with a 0.005-micron pore size, provide a unique alternative to charged membrane solutions and feature one of the smallest pore sizes available, potentially offering superior microbial and endotoxin retention compared to competitors like Cytiva (formerly Pall Corporation), Aquatools, Aquamedix, and i3.
• Nephros filters are distinguished by exceptional membrane surface area and longer service life compared to competitors, which can lead to improved cost-effectiveness and reduced maintenance in critical-use environments.
• The new PFAS reduction solution positions Nephros to address emerging contaminants, potentially setting a new standard for comprehensive water quality protection in commercial and federally regulated facilities, an area where traditional competitors like 3M Company and Pentair may have varying levels of specialized offerings.

Corporate Governance

Legal Proceedings

• No material pending legal proceedings.
• No governmental authority contemplating any material proceeding.

Related Party Transactions

• Wexford Capital L.P. and its affiliates beneficially owned approximately 34% of outstanding common stock as of March 1, 2026, and collectively with directors and executive officers, owned approximately 37.5%. This concentration of voting power allows Wexford to exert significant influence over corporate policies and affairs, including director elections, and could delay or prevent a change of control.

Stakeholder Impact

• Shareholders: Positive financial results and improved liquidity could increase shareholder value, but the material weakness in internal controls and potential dilution from future equity issuances pose risks. Wexford Capital's significant ownership provides substantial influence.
• Employees: Increased R&D and SG&A expenses due to headcount and bonuses indicate investment in personnel. The company aims to maintain good relations and a well-regarded workplace.
• Customers: Continued product development, including PFAS reduction, and focus on service and support aim to enhance customer satisfaction and safety, particularly in healthcare and dialysis settings.
• Suppliers: The extended exclusive supply agreement with Medica S.p.A. solidifies a key relationship, but minimum purchase requirements and potential tariff impacts could affect the supplier relationship and costs.
• Creditors: Improved net income and positive operating cash flow enhance the company's financial stability, potentially reducing credit risk.

Next Steps

• Continue efforts to promote, market, and increase sales of Medica Products in the Territory.
• Schedule periodic discussions between Medica's representatives and Nephros personnel to facilitate information dissemination.
• Inform customers of promotional and marketing programs.
• Prominently display and actively promote Medica Products at tradeshows.
• Employ and maintain sufficient professional service representatives for promotion, marketing, and sales.
• Continue to develop solutions to meet customer needs for ultrafiltration systems.
• Pursue alliance opportunities for joint product development and/or distribution for ultrafilter products.
• Assess the effects of new temporary global tariffs on costs and margins.
• Remediate the identified material weakness in internal control over financial reporting by operating applicable controls for a sufficient period and confirming effectiveness through testing.
• Continue to evaluate opportunities to expand into new verticals where filtration technologies provide measurable value.
• Continue to develop and explore ways to collaborate with employees and create a well-regarded workplace.

Key Dates

Recommendation

Nephros, Inc. demonstrated strong financial performance in 2025 with a substantial increase in net income and revenue, coupled with positive operating cash flow. The extension of the key supply agreement with Medica and the introduction of a PFAS reduction solution indicate strategic product development and market expansion. While the identified material weakness in internal controls and ongoing tariff uncertainties warrant monitoring, the overall trajectory of improved profitability and liquidity suggests a positive outlook for investors. The company's focus on high-growth medical and emerging commercial water filtration markets, backed by FDA clearances and proprietary technology, positions it for continued growth.

Keywords

Water filtration, Medical devices, Infection control, Dialysis water, PFAS reduction, SEC filing, 10-K, Financial results, Revenue growth, Net income, Supply chain, Tariffs, Internal controls, FDA 510(k), Healthcare, Commercial filtration, Medica S.p.A., Corporate governance, Risk factors